Company
Thabor Therapeutics
Changing the course of mucosal inflammatory diseases by blocking extracellular AGR2 to reinstate mucosal homeostasis
- Status
- Operatingas of 2026-09-21
- Business model
- B2B
- Headquarters
- Paris, France
- Legal name
- Thabor Therapeutics
Claim, correct or request removal
Record updated 28 September 2026
About
Thabor therapeutics is an INSERM spin off developing a first-in-class therapeutic antibody targeting AGR2 for the treatment of inflammatory mucosal diseases.
Loading relationship preview